Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pheniramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | SCN1A | P35498 | 3/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 3/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.81 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.81 |
| ▸ | HTR2A | P28223 | 4/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.81 |
| ▸ | THPO | P40225 | 2/20 | 0.81 |
| ▸ | DRD1 | P21728 | 2/20 | 0.81 |
| ▸ | HTR2C | P28335 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pheniramine SCHEMBL48720 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| Pheniramine SCHEMBL4796 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| Pheniramine SCHEMBL30182646 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| Pheniramine SCHEMBL365145 | 0.98 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| Pheniramine SCHEMBL18240052 | 0.98 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| Chlorpheniramine SCHEMBL10622596 | 0.91 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| Dexbrompheniramine SCHEMBL28086608 | 0.91 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| SCHEMBL11615820 | 0.91 | CHRM2 (0.83) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| SCHEMBL14198390 | 0.91 | CHRM2 (0.83) | CHRM2SLC6A2SLC6A4SCN1ASCN2A | |
| Dexbrompheniramine SCHEMBL15516617 | 0.90 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | claimed |
| WO-2024163315-A2 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | DEVORE DALE (US) | 2024-08-08 | — | — | WO | claimed |
| US-20240252446-A1 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | SUSTAINED DRUG DELIVERY LLC | 2024-08-01 | — | — | US | claimed |
| CN-117979991-A | Methods for treating, ameliorating or preventing infections using drug and vaccination combination therapy | 拓比利亚欧斯特有限公司(ACN 652 771 670) | 2024-05-03 | — | — | CN | claimed |
| US-11957682-B2 | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-04-16 | — | — | US | claimed |
| US-11946928-B2 | Methods and compositions relating to airway dysfunction | TRUSTEES OF BOSTON UNIVERSITY | 2024-04-02 | — | — | US | claimed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | claimed |
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LTD ACN 652 771 670 (AU) | 2024-03-07 | — | — | US | claimed |
| CN-116963744-A | Pharmaceutical, therapeutic combination and method for preventing viral and microbial infections and their sequelae | 拓比利亚欧斯特有限公司(ACN 652 771 670) | 2023-10-27 | — | — | CN | claimed |
| EP-4262813-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | Topelia Aust Limited (ACN 652 771 670) (AU) | 2023-10-25 | — | — | EP | claimed |
| US-20060057205-A1 | Phenylepherine containing dosage form | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2006-03-16 | — | — | US | claimed |
| WO-2006022996-A2 | DOSAGE FORM CONTAINING MULTIPLE DRUGS | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2006-03-02 | — | — | WO | claimed |
| WO-2006003519-A2 | USE OF EMULSIONS FOR INTRA: AND PERIOCULAR INJECTION | NOVAGALI PHARMA SA (FR) | 2006-01-12 | — | — | WO | claimed |
| US-20060002963-A1 | Use of emulsions for intra and periocular injections | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-01-05 | — | — | US | claimed |
| EP-1611879-A1 | Use of emulsions for intra- and periocular injection | Novagali Pharma SA (FR) | 2006-01-04 | — | — | EP | claimed |
| US-20050272746-A1 | Inactive isomer compositions for use as drug-resistance-reversal agents and in prophylactic treatment | SMILKSTEIN MARTIN J | 2005-12-08 | — | — | US | claimed |
| US-20050266032-A1 | Dosage form containing multiple drugs | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2005-12-01 | — | — | US | claimed |
| WO-2005110473-A2 | METHODS AND ARTICLES FOR THE DELIVERY OF MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASES | DIRECTCONTACT LLC (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050208102-A1 | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases | DIRECTCONTACT, LLC | 2005-09-22 | — | — | US | claimed |
| US-5183665-A | Using antihistamine | NITTO DENKO CORPORATION (JP) | 1993-02-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | ACE, ACHE, SARS1 | HRH1 2890/4885CHRM2 1276/4885SLC6A2 2975/4885 |
| US-11957682-B2 | Compounds and methods for regulating, limiting, or inhibiting AVIL expression | VCL, HDLBP, VHL | HRH1 3836/4885CHRM2 3547/4885SLC6A2 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.